Revance Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Revance Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Revance Therapeutics Inc Strategy Report
- Understand Revance Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The following section provides information on Revance Therapeutics Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Revance Therapeutics Inc's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Angus C. Russell
Chairman Executive BoardMr. Angus C. Russell has been the Chairman of the company since March 2014. He has been in the Board of Directors at Mallinckrodt since August 2014, BioTime Inc since December 2014, and TherapeuticsMD Inc since March 2015. Mr. Russell served as a Director at Shire Plc from 1999 to 2013. He has been the Chief Executive Officer of Shire Plc from 2008 to 2013 and Chief Financial Officer from 1999 to 2008.
Mark J. Foley
Director; President; Chief Executive Officer Executive BoardMr. Mark J. Foley has been the Chief Executive Officer, President and a Director of the company since October 2019. Prior to this, Mr. Foley served as Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ) from 2012 to 2017, where he led the company through a period of significant transformation and growth, culminating in its acquisition by Allergan (AGN).
Tobin C. Schilke
Chief Financial Officer Senior ManagementMr. Tobin Schilke has been the Chief Financial Officer of the company November, 2018. He previously served as the Chief Financial Officer at Achaogen Inc from 2016 to 2018. Before that Mr. Schilke served for 13 years at Genentech and Roche in a variety of finance and operational roles including Director of Commercial FP&A for Genentech’s BioOncology Business, and Project Manager of M&A and Chief Financial Officer of Roche Products Ltd.
David A. Hollander, M.D
Chief Medical Officer Senior ManagementMr. David A. Hollander, M.D has been the Chief Medical Officer of the company since October 2022. Prior to this he served as a Chief Research & Development Officer at Aerie Pharmaceuticals.
Dustin S. Sjuts
President Senior ManagementStill looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer